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Tyrosinase is a bifunctional enzyme which oxidizes the initial step of melanin biosynthesis, that is, conversion of tyrosine to
dopa and subsequently dopa to dopaquinone. It is a glycosylated protein and a major regulator of melanogenesis. To date, many
approaches have been tried to regulate tyrosinase activity and melanin content. To that end, we screened small interfering RNA
sequences for sequence-inhibited tyrosinase expression in B16 cells and in C57BL/6 mice. We analyzed tyrosinase mRNA levels
by quantitative real-time PCR and determined tyrosinase activity and melanin content at 24, 48, and 72 hours after transfection.
Results showed that siNM 011661 001 was the most eﬃcient small interfering RNA sequence in suppressing tyrosinase mRNA
expression, and cells transfected with this sequence showed lower tyrosinase activity. Moreover, intravitreous injection of
siNM 011661 001inC57BL/6miceinducedaneﬃcientandstablegene-speciﬁcinhibitionofexpressionattheposttranscriptional
level.
1.Introduction
Tyrosinase mutation can induce human diseases, such as
oculocutaneous albinism. Melanin is a heterogeneous poly-
mer produced and concentrated within the melanosomes of
themelanocytes,andtyrosinaseisakeyrate-limitingenzyme
for melanin biosynthesis. Tyrosinase catalyzes three steps in
melanin biosynthesis: the hydroxylation of tyrosine to 3, 4-
dihydroxyphenylalanine (DOPA), the oxidation of DOPA to
DOPA-quinone,andtheoxidationof5,6-dihydroxyindoleto
indolequinone. Because of its central role in melanogenesis,
tyrosinase is a key target for the development of new
inhibitors [1–3].
In the present study, we aimed to directly regulate tyrosi-
naseexpressionusingRNAinterference(RNAi).Wescreened
small interfering RNAs (siRNAs) corresponding to the
tyrosinase sequence using the mouse melanoma cell line B16
and then delivered the most eﬀective sequence into C57BL/6
mice to study its eﬀect in vivo.
2.MaterialsandMethods
2.1. Cell Culture. B16 mouse melanoma cells (Shanghai
Institute of Cell Biology, Chinese Academy of Sciences) were
cultured in DMEM (GIBCO, USA), supplemented with 10%
(v/v) fetal bovine serum (Hangzhou Sijiqing Biological Engi-
neering Materials Co., Ltd., China) and 2mmol/L glutamine
(AMRESCO, USA) at 37
◦C in a humidiﬁed atmosphere
with 5% CO2 [3, 4]. The B16 cells were trypsinized and
centrifugedat1,500rpmfor5minutesandthenresuspended
in DMEM culture medium and seeded in a six-well plate
(Corning, USA) at 2 × 105 per well and 96-well plate
(Corning) at 1 × 104 per well. Cells were cultured for
12 hours and transfected when cells were at 30% to 50%
conﬂuence.
2.2. Mice. C57BL/6 mice were purchased from the Labora-
tory Animal Center at Sun Yat-sen University in China and2 Molecular Biology International
were handled in accordance with the Research in Vision and
Ophthalmology guidelines for the use of animals in research
(animal quality certiﬁcate, 0028619; animal experiment
license, SYXK [Guangdong] 2005-0058).
2.3. siRNA Design and Transfection. Twelve hours after
seeding, cells were transfected using Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer’s instruc-
tions. siRNAs were prepared by serial dilution (10–
60nmol/L) in Opti-MEM I medium (GIBCO) to deter-
mine the optimal transfection concentration. The opti-
mal transfection concentration was deﬁned as the mini-
mum concentration of siRNAs that can produce the high-
est ﬂuorescence intensity. The siRNA-targeting tyrosinase
mRNA was designed by the Dharmacon online siRNA
design tool (http://www.dharmacon.com/HomePage.aspx)
and synthesized by RuiBo Biotechnology Co., Ltd., China.
The siRNA sequences against tyrosinase were as follows:
siNM 011661 001targetsequence,AAGCGAGTCTTGATT-
AGAA; sense (5 -3 ), AAGCGAGUCUUGAUUAGAA(d-
TdT); antisense (3 -5 ), (dTdT)UUCGCUCAGAACUAA-
UCUU; siNM 011661 002 target sequence, ACAATGCCT-
TACATATCTT; sense, ACAAUGCCUUACAUAUCUU(d-
TdT); antisense, (dTdT)UGUUACGGAAUGUAUAGAA;
and siNM 011661 003 target sequence, TCATACCGCTCT-
ATAGAAA; sense, UCAUACCGCUCUAUAGAAA(dTdT);
antisense, (dTdT)AGUAUGGCGAGAUAUCUUU. The siR-
N A sw e r ea l l3  -hydroxymethylation modiﬁed.
The siRNAs were diluted to the optimal concentra-
tion according to a previous description. A Lipofectamine
2000-containing negative siRNA (green ﬂuorescence protein
mRNA sequence) group and a blank group (Lipofectamine
solution alone) were used as controls. After transfection, the
cellswereharvestedatthreediﬀerenttimepoints(24,48,and
72h) to determine the mRNA expression, melanin content,
and tyrosinase activity for each treatment. The group-
ing information is as follows: group1 (siNM 011661 001),
group2 (siNM 011661 002), group3 (siNM 011661 003),
negative controlgroup (negative siRNA), blank group (Lipo-
fectamine).
2.4. Quantitative Real-Time PCR. Tyrosinase mRNA in
siRNA-treated B16 cells was quantitatively analyzed using
quantitative real-time PCR (qRT-PCR). Total RNA extrac-
tion from B16 cells was done as previously described [5].
cDNA was synthesized with random primers using no more
than 500 ng of total RNA in each 10-μL reaction according
to the manufacturer’s instruction (TaKaRa, Japan). SYBR
Green qRT-PCR were done in a Real-Time Detection System
(ABI7000, USA) according to the manufacturer’s instruc-
tions (TaKaRa, Japan) using the comparative cycle threshold
method. β-actin mRNA was used as the internal control.
Thermalcyclerconditionswere95
◦Cfor10secondsfollowed
by40cyclesof5secondseachat95
◦Cand31secondsat60
◦C.
The primer pairs were designed for tyrosinase and β-actin
using Primer 5.0 Express Software as follows: tyrosinase for-
ward primer, 5 -GCCCAGCATCCTTCTTC-3 ; tyrosinase
reverse primer, 5 -TAGTGGTCCCTCAGGTGTTC- 3 ; β-
actin forward primer, 5 -CAGCCTTCCTTCTTGGGTAT-
3 ;a n dβ-actin reverse primer, 5 -TGGCATAGAGGTCTT-
TACGG- 3 .
2.5. Tyrosinase Activity Assay. Tyrosinase activity was
assessed by determining the catalysis of L-DOPA to dopach-
rome, which has an absorption peak at 490nm. In this study,
the inhibitory action of siRNAs on tyrosinase was assayed
as described previously [4, 6, 7] with slight modiﬁcations.
Brieﬂy, B16 cells were seeded at a density of 1 × 104 cells per
well in 96-well plates. After 12 hours, the cells were treated
with diﬀerent siRNAs and cultured for 24 to 72 hours at
37
◦C The adherent cells were washed three times with PBS
and then lysed in sodium phosphate buﬀer (0.1mol/L, pH
6.8) containing 1% Triton X-100. Then, 10μL L-DOPA (1%;
ICN, China) was added, allowed to react, and incubated
for 2 hours at 37
◦C. Absorbance was measured at 490nm
using an enzyme-linked immunosorbent assay reader
(PowerWave XS, Bio-Tek, USA). These experiments were
done in triplicate.
2.6. Assay of Melanin Content. The melanin content was
determined as described previously [4, 7–9] by alkaline lysis
with minor modiﬁcations. After transfection, adherent cells
(1 × 106) were washed with PBS, detached by trypsinization,
collected in a test tube, and then washed twice with PBS.
The cells were resuspended in 1mol/L NaOH, incubated at
80
◦C for 30 minutes, and then centrifuged at 1,500rpm for 5
minutes.Theabsorbanceofthesupernatantwasmeasuredat
475nm and compared with the standard curve of the serial
dilution of standard melanin (Sigma, USA). The melanin
content was expressed as microgram per 1 × 106 cells. The
detection was done in triplicate.
2.7.AnalysisofRetinalTyrosinasemRNAinsiNM 011661 001
Treated Mice. Mice received general anesthesia by the i.p.
injection of chloral hydrate (0.008mL/kg) and local anesthe-
sia with 2% pontocaine. With the guidance of an operating
microscope (OLYMPUS, Japan), two groups of mice were
given an intravitreous injection of 2.5μL PBS containing
either 0.65 or 1.3nmol siNM 011661 001, and 2.5μL PBS
was injected as control. The detection was done in triplicate
in every group. Twenty-four hours after injection, total RNA
extraction (QIAGEN, Germany) was done from the retina of
C57BL/6 mice as described previously [5] and analyzed with
qRT-PCR.
2.8. Statistical Analysis. Data were expressed as mean±SD.
ANOVA was used to compare the diﬀerences between the
groups using SPSS 13.0 for Windows (Chicago, USA). P<
.05 was considered statistically signiﬁcant.
3. Results
3.1. Cell Morphology. Before transfection, most cells
appeared fusiform, and some cells were reticular at low
density. The cells in the division phase showed a clearMolecular Biology International 3
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Figure 1: Light micrograph showing the morphology of B16
mouse melanoma cells before transfection. Original magniﬁcation,
× 100. Determination of the optimal siRNA concentration using
the ﬂuorescently labeled (FAM) negative control siRNA Original
magniﬁcation, × 200. The siRNA concentration used in these
experiments was 40nmol/L.
outline, an obvious boundary between cells, and a ﬁne
refractive index (Figure 1), but after transfection, the cells
swelled and the boundary between them became indistinct.
3.2.DeterminationoftheOptimalTransfectionConcentration.
Twenty-four hours after transfection, the distribution of
intracellular ﬂuorescence was sporadic in cells treated with
10,20,30,and60nmol/LsiRNA.However,intracellularﬂuo-
rescence was widespread, and the intensity was strengthened
in cells transfected with 40 and 50nmol/L siRNA (Figure 1).
In this study, we achieved the best transfection eﬃcacy
with the lowest Lipofectamine 2000 (0.2μLp e rc e l li na
96-well plate; 4μL per cell in a 6-well plate) and siRNA
concentrations (40nmol/L). Thus, we used 40nmol/L in this
study.
3.3. mRNA Expression. We evaluated the eﬃciency of each
sequence to suppress tyrosinase expression at 24, 48, and 72
hours after transfection. The results were 82.81%, 76.19%,
and 75.46% for siNM 011661 001; 75.75%, 43.49%, and
37.86% for siNM 011661 002; 50.54%, 23.66%, and 22.42%
for siNM 011661 003; 17.22%, 11.34%, and 8.68% for
the negative control sequence, respectively (Figure 2). The
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Figure 2: The eﬃcacy of each siRNA in suppressing mRNA at
diﬀerent time points. Interference eﬃciency of siNM 011661 001
(blue), siNM 011661 002 (pink), siNM 011661 003 (yellow), and
negative siRNA (green) at 24, 48, and 72 hours after transfection.
Experiments were done in triplicate. Results are presented with
respect to the Lipofectamine-treated group, which was set at 100%.
eﬃciency of the three fragments decreased gradually from 24
to 72 hours after transfection. The statistical results showed
that the siRNA sequence siNM 011661 001 was the most
eﬀective in suppressing tyrosinase expression (F = 298.566
and P<. 05 at 24h; F = 179.217 and P <. 05 at 48h;
F = 188.564 and P<. 05 at 72h).
3.4. Tyrosinase Activity. We evaluated reductions in tyrosi-
nase activity in the transfected cells at 24, 48, and 72 hours
aftertransfection.Tyrosinaseactivitywasreducedby64.73%,
40.42%,and28.74%forsiNM 011661 001;63.37%,25.06%,
and 17.33% for siNM 011661 002; 48.16%, 18.33%, and
16.65% for siNM 011661 003; 6.44%, 4.90%, and 3.56%
for the negative control sequence, respectively (Figure 3).
The tyrosinase suppression decreased with time for each
siRNA sequence, which was similar to the suppression
at the mRNA level. Overall, siNM 011661 001 had the
most powerful interference eﬃciency. After 24 hours, there
was no signiﬁcant diﬀerence between siNM 011661 001
and siNM 011661 002 (P >. 05), whereas signiﬁcant
diﬀerences were observed among the other groups (F =
58.485; P <. 05). At 48 hours, signiﬁcant diﬀerences were
observed among the groups (F = 160.208; P <. 05).
At 72 hours, no signiﬁcant diﬀerence was found between
siNM 011661 002 and siNM 011661 003, whereas signiﬁ-
cant diﬀerences were observed between the other groups
(F = 117.372; P<. 05). These results supported previous4 Molecular Biology International
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Figure 3: Detection of tyrosinase activity (OD value) at diﬀerent
time points. Absorbance was measured at 490nm to determine
dopachromeproductioninB16cellstreatedwithsiNM 011661 001
(blue), siNM 011661 002 (pink), siNM 011661 003 (yellow), neg-
ative siRNA (green), and Lipofectamine (brown).
ﬁndings that siNM 011661 001 most eﬀectively suppressed
tyrosinase expression.
3.5. Melanin Content. The decrease in melanin content
in each group was evaluated at days 1, 2, and 3. The
percent reduction in melanin was 52.53%, 48.55%, and
32.73% for siNM 011661 001; 25.59%, 21.61%, and 6.15%
for siNM 011661 002; 21.01%, 18.79%, and 1.70% for
siNM 011661 003; 5.53%, 3.58%, and 1.00% for the neg-
ative control sequence, respectively (Figure 4). After 48
hours, the melanin content and interference eﬃciency of
siNM 011661 002 and siNM 011661 003 were not signiﬁ-
cantly diﬀerent. However, after 72 hours, cells transfected
with siNM 011661 001 contained signiﬁcantly less melanin
than the other groups (P <. 05), whereas comparisons
between other groups were not signiﬁcantly diﬀerent.
3.6. Measurement of mRNA Expression of Tyrosinase In Vivo.
Because siNM 011661 001 most eﬀectively reduced mRNA
expressionoftyrosinase inB16cells,weevaluatedits eﬀectin
C57BL/6 mice. To determine the change in tyrosinase mRNA
levels, qRT-PCR was carried out using tyrosinase-speciﬁc
primers and total RNA isolated from retinas (Table 1).
Negative interference sequence and liposome (blank group)
have nonspeciﬁc interference eﬀect during our experiment.
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Figure 4: Detection of melanin content at diﬀerent time points.
The absorbance was measured at 475nm and compared with
the standard curve made by the serial dilution of standard
melanin. The melanin content was expressed as microgram per
1 × 106 cells. Melanin content was determined in B16 cells
treated with siNM 011661 001 (blue), siNM 011661 002 (pink),
siNM 011661 003 (yellow), negative siRNA (green), and Lipo-
fectamine (brown) at 24, 48, and 72 hours after transfection.
Experiments were done in triplicate.
Table 1: The tyrosinase mRNA levels in mice receiving diﬀerent
dosages of siNM 011661 001.
Dosage 0.65nmol
siNM 011661 001
1.3nmol
siNM 011661 001
Interference
eﬃciency∗ 25.25%±0.0355 59.85%±0.0276
∗Twenty-four hours after injection, qRT-PCR showed that the tyrosinase
levelsintheretinasofmicetreatedwith0.65and1.3nmolsiNM 011661 001
siRNA were reduced by 25.25%±0.0355 and 59.85%±0.0276 (P < .05),
respectively, compared with retinas of eyes injected with PBS.
4. Discussions
All three siRNA sequences that we screened suppressed
tyrosinase expression, but siNM 011661 001 was most
eﬀective, exerting the maximum eﬀect at 24 hours after
transfection. It is presumed that tyrosinase mRNA pos-
sesses a special functional structure that is most similar to
siNM 011661 001.Thedatapresentedheresuggestsacrucial
role for siRNA structure in RNAi [8, 10].
In this study, the suppressive eﬀects on melanogenesis in
B16 cell line peaked at 24 hours, suggesting that siRNA was
active for 24 hours after transfection and then was gradually
degraded. However, we used modiﬁed siRNA, which can
enhance stability and reduce the potential for oﬀ-target
eﬀects. Sequences of siRNA for a target gene do not perform
equally, but signiﬁcant progress has been made in deﬁningMolecular Biology International 5
sequence features that contribute to siRNA potency. Low
internal stability at the 5  terminus of antisense siRNA is an
important prerequisite for gene silencing. Excessive stability
can result in double-strand unwinding, but inferior stability
can reduce the aﬃnity of siRNA to its mRNA target [11].
In the present study, we noted an interesting phe-
nomenon: siNM 011661 001 transfection resulted in the
considerable suppression of tyrosinase mRNA compared
with other control siRNAs. Further experiments are needed
to support this ﬁnding.
Furthermore, the negative controls (siRNA sequence and
Lipofectaminetransfectionreagent)wereobservedtoslightly
reducemelanincontentwithtime(Figure 4),whichwassim-
ilar to the eﬀect of siNM 011661 002 and siNM 011661 003
72 hours after transfection. This phenomenon also appeared
at the level of gene expression and tyrosinase activity,
suggesting nonspeciﬁc RNAi activity. Thus, negative control
siRNA should be selected carefully.
In addition to showing that siNM 011661 001 is the
most potent siRNA sequence against tyrosinase in B16
cells, we assessed the eﬀect of this siRNA sequence on
tyrosinaseexpressioninC57BL/6mice.Oneoftheimportant
factors for RNAi eﬀectiveness in vivo may be the delivery
and transfection eﬃciency of siRNAs. In mammalian cells,
siRNA has been administered locally or systemically, and
the eﬃciency of RNAi delivery systems is still relatively low.
Previous studies showed that the systemic delivery of siRNAs
by tail vein injection does not deliver siRNAs eﬃciently to
their target areas because siRNA molecules are easily trapped
in nonspeciﬁc organs. We thought that the optimal eﬃcacy
of siRNA targeting pigmentary epithelium would be largely
deprived via intravenous injection, because the nutrient
vessel supporting pigmentary epithelium belongs to distal
circulation vessel. What is more, the synthetic siRNA pieces
are heterogenous to mice; appearance of these heterogenous
pieces in circulation may potentially induce severe immune
lesion to mice. In contrast, intravitreous treatment may have
its advantage to overcome these problems, because vitreous
space has the immediate proximity to retina, the small
molecular weight of siRNA may be eﬃciently delivered to
retina and pigment epithelium through posterior vitreous
membrane and thus have direct eﬀects on target tissues. In
addition, the blood-ocular barrier may function to prevent
the entry of intravitreously injected siRNA into circulation.
In summary, intravitreous administration may take many
advantagesbeyondintravenousinjection,duetoeﬃcientand
direct delivery of siRNA pieces to target tissues combined
with reduced risk of inducing side eﬀects. After considering
these factors collectively, we chose intravitreous injection
throughout this work. We also believe that this method
would provide a new approach to ocular albinism mouse
model preparation. In contrast, our results showed that
siRNA administered locally had signiﬁcant inhibitory eﬀects
on the retina. It strongly suggests that siNM 011661 001 can
be delivered eﬀectively in vivo and may also be delivered to
other tissues such as skin and hair.
In summary, we have shown that siNM 011661 001-
targeting tyrosinase is the most potent sequence in vitro and
in vivo. RNAi is a new tool for gene silencing using antisense
nucleic acids [12] and gene targeting [13]. In addition,
it gives us a new method to use in the development of
pigmentation disease (e.g., ocular albinism) animal models
and treatments. Furthermore, this technique may be useful
in the study of downstream factors of tyrosinase.
Acknowledgments
The authors thank Zhu Qiangfeng for the technical support
and the laboratory personnel of the Oncology Center of
Sun Yat-sen University. This work was supported by the
National Natural Science Foundation of China (30640047)
and the Guangdong Province Science and Technology Pro-
gram (2006B60101058).
References
[1] K. U. Schallreuter, S. Kothari, B. Chavan, and J. D. Spencer,
“Regulation of melanogenesis-controversies and new con-
cepts,” Experimental Dermatology, vol. 17, no. 5, pp. 395–404,
2008.
[ 2 ] J .D .S i m o n ,D .P e l e s ,K .W a k a m a t s u ,a n dS .I t o ,“ C u rr e n tc h a l -
lenges in understanding melanogenesis: bridging chemistry,
biological control, morphology, and function,” Pigment Cell
and Melanoma Research, vol. 22, no. 5, pp. 563–579, 2009.
[3] J.-Y. Yang, J.-H. Koo, Y.-G. Song et al., “Stimulation of
melanogenesis by scoparone in B16 melanoma cells,” Acta
Pharmacologica Sinica, vol. 27, no. 11, pp. 1467–1473, 2006.
[ 4 ]Y .J .K i m ,J .K .N o ,J .S .L e e ,M .S .K i m ,a n dH .Y .C h u n g ,
“Antimelanogenic activity of 3,4-dihydroxyacetophenone:
inhibition of tyrosinase and MITF,” Bioscience, Biotechnology
and Biochemistry, vol. 70, no. 2, pp. 532–534, 2006.
[5] J. D¨ orrie, V. Wellner, E. K¨ ampgen, G. Schuler, and N. Schaft,
“ A ni m p r o v e dm e t h o df o rR N Ai s o l a t i o na n dr e m o v a lo f
melanin contamination from melanoma tissue: implications
for tumor antigen detection and ampliﬁcation,” Journal of
Immunological Methods, vol. 313, no. 1-2, pp. 119–128, 2006.
[6] M. Nakajima, I. Shinoda, Y. Fukuwatari, and H. Hayasawa,
“Arbutin increases the pigmentation of cultured human
melanocytes through mechanisms other than the induction of
tyrosinase activity,” Pigment Cell Research, vol. 11, no. 1, pp.
12–17, 1998.
[7] H. Ando, Y. Funasaka, M. Oka et al., “Possible involvement of
proteolytic degradation of tyrosinase in the regulatory eﬀect
of fatty acids on melanogenesis,” Journal of Lipid Research, vol.
40, no. 7, pp. 1312–1316, 1999.
[8] A.S.PeekandM.A.Behlke,“Designofactivesmallinterfering
RNAs,” Current Opinion in Molecular Therapeutics, vol. 9, no.
2, pp. 110–118, 2007.
[9] M. Ishikawa, I. Kawase, and F. Ishii, “Combination of
amino acids reduces pigmentation in B16F0 melanoma cells,”
Biological and Pharmaceutical Bulletin, vol. 30, no. 4, pp. 677–
681, 2007.
[10] I. Brad´ aˇ c, R. Svobodov´ aV aˇ rekov´ a, M. Wacenovsky, M. ˇ Skrdla,
M. Plch´ ut, and M. Polˇ c´ ık, “siRNA selection criteria-Statistical
analyses of applicability and signiﬁcance,” Biochemical and
Biophysical Research Communications, vol. 359, no. 1, pp. 83–
87, 2007.
[11] A. Reynolds, D. Leake, Q. Boese, S. Scaringe, W. S. Marshall,
and A. Khvorova, “Rational siRNA design for RNA interfer-
ence,” Nature Biotechnology, vol. 22, no. 3, pp. 326–330, 2004.6 Molecular Biology International
[12] Y. Higashi, M. Asanuma, I. Miyazaki, and N. Ogawa, “Inhi-
bition of tyrosinase reduces cell viability in catecholaminergic
neuronal cells,” Journal of Neurochemistry,v o l .7 5 ,n o .4 ,p p .
1771–1774, 2000.
[13] S. Boonanuntanasarn, G. Yoshizaki, K. Iwai, and T. Takeuchi,
“Molecular cloning, gene expression in albino mutants and
gene knockdown studies of tyrosinase mRNA in rainbow
trout,”PigmentCellResearch,vol. 17,no.4, pp.413–421, 2004.